Prelude Therapeutics Clears FDA Hurdle for Novel Breast Cancer Drug
Event summary
- FDA cleared Prelude's IND application for PRT13722, an oral KAT6A selective degrader targeting HR+/HER2- breast cancer.
- Phase 1 trial enrollment expected to begin in Q4 2026.
- PRT13722 is designed to address toxicity issues of dual KAT6A/B inhibitors by selectively degrading KAT6A.
- Study will evaluate safety, tolerability, pharmacokinetics, and antitumor activity as monotherapy and in combination therapies.
The big picture
Prelude's IND clearance positions it in the growing field of targeted protein degradation, a strategy gaining traction in precision oncology. The company's focus on selective KAT6A degradation addresses a key limitation of current therapies, potentially expanding treatment options for HR+/HER2- breast cancer patients. Success in this Phase 1 trial could validate Prelude's approach and attract partnership interest in an oncology market increasingly valuing differentiated mechanisms.
What we're watching
- Clinical Validation
- How PRT13722's selective degradation approach will perform in human trials compared to dual KAT6A/B inhibitors.
- Combination Therapies
- Whether PRT13722 can demonstrate improved efficacy and safety when combined with endocrine and targeted therapies.
- Regulatory Pathway
- The pace at which Prelude can advance PRT13722 through clinical development given the competitive landscape in HR+/HER2- breast cancer treatments.